Skip to main content

Atossa Therapeutics, Inc 8-K, filed Nov 10, 2026

Atossa Therapeutics, Inc. (ATOS)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Atossa Therapeutics, Inc filed this 8-K on November 10, 2026.

Atossa Therapeutics, Inc. said CVR holders are entitled to 25% of net proceeds from monetizing its first priority review voucher, capped at $50 million. Third-quarter operating expenses were $5.9 million, down from $9.3 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits